Specifically, decreases in quality-of-life during IFN-α treatment for advanced melanoma were offset by reduced risk of recurrence and mortality when vignette-based utilities were applied (Kilbridge et al, 2002; Crott, 2004; Crott et al, 2004). The gene discussed is IFNA1; the disease is melanoma.